Ayala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage Study
Ayala Pharmaceuticals Inc (NASDAQ:AYLA) announced interim results from Part A of the ongoing RINGSIDE Phase 2/3 trial evaluating AL102 in desmoid tumors. MRI scans showed decreases in tumor size in most of the 13 patients who had reached the 16-week point. One patient reached an unconfirmed partial response at week 16. AL102 was…
Benzinga ·
Benzinga
